<DOC>
	<DOCNO>NCT02388906</DOCNO>
	<brief_summary>The purpose study determine whether nivolumab good ipilimumab prevent recurrence melanoma .</brief_summary>
	<brief_title>Efficacy Study Nivolumab Compared Ipilimumab Prevention Recurrence Melanoma After Complete Resection Stage IIIb/c Stage IV Melanoma ( CheckMate 238 )</brief_title>
	<detailed_description>Italy , Greece , Argentina : ≥ 18 year age</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com At least 15 year age Except : local regulation and/or institutional policy allow subject &lt; 18 year age ( pediatric population ) participate . For site , eligible subject population ≥ 18 year age Completely remove melanoma surgery perform within 12 week randomization Stage IIIb/C Stage IV complete resection No previous anticancer treatment Ocular uveal melanoma History carcinomatosis meningitis History autoimmune disease Treatment direct resected melanoma administrate surgery</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>